Concepts (109)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 7 | 2020 | 297 | 0.760 |
Why?
|
| Pre-Eclampsia | 3 | 2012 | 66 | 0.730 |
Why?
|
| Blood Pressure | 10 | 2020 | 862 | 0.700 |
Why?
|
| Antihypertensive Agents | 6 | 2020 | 352 | 0.580 |
Why?
|
| Hypertension | 8 | 2020 | 976 | 0.580 |
Why?
|
| Kidney Failure, Chronic | 3 | 2017 | 543 | 0.570 |
Why?
|
| Cardiovascular Diseases | 5 | 2019 | 1140 | 0.460 |
Why?
|
| Glomerular Filtration Rate | 7 | 2020 | 309 | 0.430 |
Why?
|
| Complement Pathway, Alternative | 1 | 2013 | 1 | 0.400 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2013 | 4 | 0.400 |
Why?
|
| Complement C3 | 1 | 2013 | 8 | 0.400 |
Why?
|
| Kidney Glomerulus | 1 | 2013 | 30 | 0.390 |
Why?
|
| Death, Sudden | 1 | 2012 | 8 | 0.370 |
Why?
|
| Renal Dialysis | 1 | 2012 | 280 | 0.310 |
Why?
|
| Placentation | 1 | 2008 | 4 | 0.300 |
Why?
|
| Placenta | 1 | 2008 | 75 | 0.280 |
Why?
|
| Patient Care Planning | 1 | 2006 | 58 | 0.230 |
Why?
|
| Apolipoproteins | 2 | 2016 | 200 | 0.200 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 252 | 0.200 |
Why?
|
| Humans | 18 | 2020 | 32798 | 0.190 |
Why?
|
| Cause of Death | 3 | 2017 | 240 | 0.190 |
Why?
|
| Heart Failure | 3 | 2017 | 695 | 0.180 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 599 | 0.170 |
Why?
|
| Cystatin C | 1 | 2020 | 32 | 0.160 |
Why?
|
| Female | 13 | 2020 | 20261 | 0.160 |
Why?
|
| Risk Factors | 6 | 2020 | 3974 | 0.160 |
Why?
|
| Creatinine | 1 | 2020 | 198 | 0.160 |
Why?
|
| Kidney Tubules | 1 | 2019 | 26 | 0.160 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 754 | 0.160 |
Why?
|
| Pregnancy | 3 | 2012 | 981 | 0.150 |
Why?
|
| Aged | 10 | 2020 | 10538 | 0.150 |
Why?
|
| Adenine Phosphoribosyltransferase | 1 | 2018 | 3 | 0.150 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2018 | 4 | 0.150 |
Why?
|
| Urolithiasis | 1 | 2018 | 7 | 0.150 |
Why?
|
| Nephritis, Interstitial | 1 | 2018 | 9 | 0.150 |
Why?
|
| Kidney Calculi | 1 | 2018 | 23 | 0.140 |
Why?
|
| Hospitalization | 1 | 2020 | 488 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 2 | 2017 | 203 | 0.130 |
Why?
|
| Blood Pressure Determination | 4 | 2020 | 102 | 0.130 |
Why?
|
| Nitrates | 1 | 2017 | 28 | 0.130 |
Why?
|
| Middle Aged | 9 | 2020 | 12125 | 0.130 |
Why?
|
| Male | 10 | 2020 | 19641 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2017 | 187 | 0.120 |
Why?
|
| Myocardial Infarction | 2 | 2017 | 483 | 0.120 |
Why?
|
| Kidney Diseases | 1 | 2016 | 250 | 0.100 |
Why?
|
| Antigen-Antibody Complex | 1 | 2013 | 4 | 0.100 |
Why?
|
| Microscopy, Electron | 1 | 2013 | 30 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 91 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 4032 | 0.090 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2012 | 14 | 0.090 |
Why?
|
| Calcium Carbonate | 1 | 2012 | 8 | 0.090 |
Why?
|
| Biopsy | 1 | 2013 | 245 | 0.090 |
Why?
|
| Exercise | 1 | 2017 | 679 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 2284 | 0.090 |
Why?
|
| Incidence | 2 | 2017 | 1238 | 0.080 |
Why?
|
| Galectins | 1 | 2008 | 5 | 0.070 |
Why?
|
| Serum Amyloid P-Component | 1 | 2008 | 3 | 0.070 |
Why?
|
| Angiogenic Proteins | 1 | 2008 | 10 | 0.070 |
Why?
|
| Pregnancy Proteins | 1 | 2008 | 10 | 0.070 |
Why?
|
| Systole | 2 | 2020 | 98 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2008 | 60 | 0.070 |
Why?
|
| Age Factors | 2 | 2016 | 1197 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2008 | 49 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2008 | 69 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2008 | 101 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 237 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 887 | 0.060 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 107 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 205 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2020 | 3438 | 0.060 |
Why?
|
| Adolescent | 1 | 2013 | 3638 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 470 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 682 | 0.050 |
Why?
|
| Comorbidity | 1 | 2006 | 573 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 622 | 0.050 |
Why?
|
| Antimetabolites | 1 | 2018 | 11 | 0.040 |
Why?
|
| Allopurinol | 1 | 2018 | 12 | 0.040 |
Why?
|
| African Americans | 2 | 2016 | 1424 | 0.040 |
Why?
|
| Reference Standards | 1 | 2017 | 32 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2006 | 3701 | 0.030 |
Why?
|
| Nitrites | 1 | 2017 | 22 | 0.030 |
Why?
|
| Beta vulgaris | 1 | 2017 | 11 | 0.030 |
Why?
|
| Physical Endurance | 1 | 2017 | 35 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 271 | 0.030 |
Why?
|
| Critical Care | 1 | 2017 | 108 | 0.030 |
Why?
|
| Oxygen | 1 | 2017 | 144 | 0.030 |
Why?
|
| Inflammation | 1 | 2019 | 536 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1572 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 764 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 315 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 881 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2017 | 370 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 532 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2014 | 246 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 2183 | 0.020 |
Why?
|
| Cognition | 1 | 2016 | 551 | 0.020 |
Why?
|
| Antacids | 1 | 2012 | 4 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 1460 | 0.020 |
Why?
|
| Stroke | 1 | 2017 | 609 | 0.020 |
Why?
|
| Gestational Age | 1 | 2012 | 129 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 91 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 525 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 1307 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2012 | 410 | 0.020 |
Why?
|
| Brain | 1 | 2016 | 946 | 0.020 |
Why?
|
| United States | 1 | 2017 | 4108 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 1462 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 2327 | 0.020 |
Why?
|
| Adult | 1 | 2012 | 9560 | 0.010 |
Why?
|